

# INDEX

- Absorption, 275  
ABT-100 (a farnesyl transferase (FT) inhibitor), 73, 74, 81  
Acetylation, enzymatic, 69  
Acylation, 89  
ADME, 209  
Air Classification Mills, 262  
Alkylation, of amino acid neutral form, 4  
Alkylation, of amino acid zwitterion, 4  
Alkylation: *N*- vs. *O*-, 2, 3  
Ammonia, 6, 7  
Amorphous, 230  
Amprenavir (Agenerase), 54, 55  
Angiogenesis, 21  
Annulation, 24  
Antibiotic, broad-spectrum, 4  
Anti-mitotic agents, 37  
Antisolvent, 253  
API (active Pharmaceutical ingredient), 32, 54, 64, 70  
Area under curve (AUC), 58, 60, 62, 64, 65  
Atazanavir sulfate (Reyataz), 56  
Audit, 115, 126  
Automation, 129  
Baylis-Hillman condensation, 87, 88, 89  
BCSA (*D*- $\alpha$ -bromocamphorsulfonic acid), 9  
Bioavailability, 15, 271  
Biocatalysis, 40  
Bio-reduction, 39, 40, 41, 48  
bis(cyclohexanecarbonitrile), 1,1-azo (VAZO), 41  
bis-trimethylsilyltrifluoroacetamide (BSTFA), 10, 12  
Bromination, benzylic, 39  
bromoacetaldehyde diethyl acetal, 17  
BSTFA: see bis-trimethylsilyltrifluoroacetamide  
Butylated hydroxytoluene (BHT), 88  
Cancer, 21  
Capsules, 285  
Carbonylation, with palladium catalysts, 90, 91, 93

- Cefoxitin, 5  
Chemical Engineering, 163  
Chemical Engineers, 10  
Chirality, 5  
Claims, 300  
Cleaning, 185  
Clinical evaluation, 21  
Co-crystallization, 3  
Conglomerate, 7  
Containment, 169  
Control Loop, 174  
Cost, 120  
Critical Parameter, 135  
Crixivan, 5  
Crown ether (18-crown-6), 43  
Cryptophycine 52, 37  
Crystallinity, 221  
Crystallization, 62, 94, 180, 247–254  
Current Good Manufacturing Practice (cGMP), 23, 31, 34, 35  
Cyclization, oxidative, 67, 68  
Cyclization, oxidative: mechanistic rationale for, 67
- DDQ/BSTFA oxidation, 10, 12  
Deazapurine, 16, 17  
Decarboxylation, 24  
Deprotection, 2  
DeShong coupling, 30  
Design of Experiment, 143  
Desilylation, 42  
Deuterofluoroacetate, 6  
Deuteration, deuterium incorporation, 5, 8  
Deuteroacetic acid (AcOD), 5  
Diabetic peripheral neuropathy, 85  
Dialkylation, 2  
Diastereomeric salts, 3  
Diastereoselectivity, 40  
Diastereoselectivity, in bio-reduction, 40  
Diels-Alder dimerization, 92  
Differential Scanning Calorimetry, 223  
Dihydrofuran, 3-acetoxyacetyl, 66  
Dissolution, 275  
Distillation, 179  
Distribution, 282  
Documentation, 106  
DOE see Design of Experiment  
Drug Metabolism, 207  
Drug Product, 269  
Drug supply, 15  
Drying, 182  
Dust Explosivity, 255
- Elimination, of HF, 8  
Enantioselective synthesis, 47, 48  
Engineering, 163  
Engineers, 10, 12, 13  
Epoxidation, 48  
Equilibria, in a chemical process, 7  
Ethyl (4-cyanophenyl)oxoacetate, 76  
Ethyl lactate (*S*), 14  
Evaporative crystallization, 254  
Excipients, 280  
Excretion, 282  
Exemption, 315  
Experimental Design, 143  
Extraction, 178
- Factorial Design, 147  
Filtration, 182  
Finasteride, 10, 11, 12  
Fludalanine (2-deutero-3-fluoro-*D*-alanine), 4, 9, 10, 13, 14  
Fluidized Energy Mills, 260  
Fluorination (HF/SF<sub>4</sub>) of (*R*)-2*D*-serine, 9  
Formulation, 5, 269, 284, 311  
Fosamprenavir calcium (Lexiva), 54, 56  
Freedom to Operate, 104  
FTO see Freedom to Operate  
Fungicides, 37
- Genotoxic Impurities, 109  
Gilson Liquid Handler, 138  
GLP see Good Laboratory Practice  
GMP see Good Manufacturing Practices  
Good Laboratory Practice, 106  
Good Manufacturing Practices, 105, 121, 166  
Grignard reagent, 75, 77  
GW640385X (anti-viral), 53, 70
- Half-life, 191, 272  
Halogen-metal exchange, 27  
Hammer Mills, 261  
Hardware, 136  
Heat Transfer, 171  
Heck coupling, 28  
Hemiacetal, 44

- Hepatitis C, 16  
High Shear milling, 254  
HIV protease inhibitor (HIV PI), 53, 65  
Hiyama coupling, 28  
Horner-Emmons condensation, 95  
Horner-Wittig reagent/reaction, 44, 45, 47  
Human immunodeficiency virus (HIV) protease, 53  
Hydrate, 233  
Hydrogenation, 40, 68, 94, 97  
Hydrogenation, asymmetric, 40, 85, 87, 93, 95, 97, 98, 99
- Ibuprofen, 10, 14  
ICH see International Conference on Harmonization  
Imipenem, 5  
Impact Mills, 261  
Impinging Jet Crystallization, 253  
Impurities, 11, 54, 59, 60, 62, 64, 65, 88, 108, 141  
Impurities, management of, 54  
Impurities, management strategy with changing route, 58  
Impurity, 26  
Indinavir (Crixivan), 53, 55  
Informatics, 143  
Inhaled, 288  
Intellectual Property, 103, 295  
International Conference on Harmonization, 108, 140  
Invention, 296  
Inventorship, 299  
IP see Intellectual Property  
Isotope Effect, 190
- Kaletra (opinavir with ritonavir), 55  
Ketalization, 132  
Ketene, 13, 14  
Kinetic hygroscopicity, 222  
Kinetics, 153  
Knoevenagel condensation, 85  
Kobayashi coupling, 29  
Kumada-Tamao coupling, 29
- Lewis acids, activation in organozinc addition, 77  
Licensing, 104  
Lithiation, 24, 26, 27, 30, 31, 34, Lopinavir (Aluviran), 55
- Macrolactamization, 48  
malononitrile, 17  
Maximum absorbable dose, 218  
Meldrum's acid, 23, 24  
Menthol, 76  
Metabolism, 282  
Metabolites, 309  
Methyldopa, 2, 3, 4, 7  
Milling, 258–264  
Mitsunobu reaction, 4  
Modified-Release, 283, 286  
*Mortierella-Isabellina* reductase, 40
- NaBH<sub>4</sub>: see Sodium borohydride, 78  
Negishi coupling, 25, 26, 27, 28, 30  
Nelfinavir (viracept), 53, 56  
Neuropathic pain, 85  
Nitrile, reduction with Ni/H<sub>2</sub>, 98  
Nonsteroidal anti-inflammatory drugs (NSAIDs), 14
- OEL, 168  
Olefination, Horner-Emmons, 41  
Optical rotation, 11  
Orange Book, 314  
Organoboron reagent, 22  
Organomagnesium reagent, 22, 23  
Organometallics, addition to  $\alpha$ -keto esters, 75  
Organostannane reagent, 22, 23, 25, 27, 31  
Organozinc reagent, 22, 23, 25, 26, 27, 77  
Outsourcing, 1, 16, 17, 113  
Oxazoline, 8  
Oxidation, 27, 43, 45, 89, 148  
Oxidation, DDQ/BSTFA, 10, 12  
Ozonolysis, 66
- PAI see Pre-approval Inspection  
Palladium, 25, 26, 27, 32, 34, 35, 91, 92  
Pantolactone (*R*), 14  
Parallel Experimentation, 136  
Parenteral, 287  
Particle Size, 247–266  
PAT see Process Analytical Technology

- Patent Cooperation Treaty, 296  
Patent, 295  
PCT see Patent Cooperation Treaty  
Perlog's rule, 75  
Permeability, 279  
PET see Positron Emission Tomography  
Pharmacokinetics, 271, 273  
Photchlorination, 5  
Photochemistry, 66  
Photofluorination, of *D*-alanine, 5  
Photohalogenation, 5  
Photoreactors, 5  
Phthalic anhydride, 17  
Physical organic chemistry, 2, 4  
Physicochemical Properties, 275  
Pivaloyloxyethyl (POE), 2, 3  
Polarized light microscopy, 222  
Polymorph, 238, 273, 307  
Positron Emission Tomography, 203  
Powder x ray, 240  
Pre-approval Inspection, 116  
Preclinical development, 54  
Preclinical evaluation, 73  
Pregabalin ( $\alpha\delta$  ligand; antiepileptic), 85, 86, 87, 97, 98  
Pregabalin, mandelate salt, in resolution, 86  
Process Analytical Technology, 186  
Process Knowledge, 159  
Prodrugs, 309  
Project Management, 122  
Protection, 2  
Provisional application, 296
- Qualification, 108  
Quality, 121
- Radioisotope, 189  
Radiolytic self-decomposition, 202  
Radiotracer, 190  
Reactive Crystallization 253  
Reactor, 171  
Recrystallization, 33, 64, 70, 86, 94  
Reduction, 66, 67, 78, 153  
Reduction, DIBAL, 41, 43, 44  
Reductive amination: of 3-fluoropyruvate, 6, 9  
Regioselectivity, in imidazole lithiation, 26
- Regulatory Interactions, 107  
Resolution, 66, 87  
Resolution, continuous, 7  
Resolution-racemization, 9, 15  
Responsibilities, 102  
Ribose, 16, 17  
Ribose, protected, 16, 17  
Rotinavir (Norvir), 56
- Safety assessment, 15  
Safety issue, 15  
Safety, 5, 166  
Salt Forms, 305  
Sampling, 176  
Saponification, 23, 94, 96  
Saquinavir (Fotovase), 55  
Saquinavir mesylate (Invirase), 55  
Scale-up, 1, 165  
Scintillation Proximity Assay, 206  
Scrubber, 184  
Selective *O*-alkylation of amino acids, 2  
Selective oxidation, primary vs. secondary alcohol, 43  
Sharpless Asymmetric Epoxidation (SAE), 39, 42  
Silyl migration, 31  
Silylation, 10, 42, 43  
Single crystal X ray, 236  
Sodium Borodeuteride, 7, 8  
Sodium borohydride ( $\text{NaBH}_4$ ), 78  
Sodium borohydride: Selective reduction of ester, 79  
Solid state NMR, 237  
Solubility limited absorption, 217  
Solubility, 278  
Solution, 286  
SOP see Standard Operating Procedures  
SPA see Scintillation Proximity Assay  
Stability, 229  
Standard Operating Procedures, 106, 121  
Stereochemistry, 40  
Stereoisomers, 308  
Stille coupling, 23, 24, 27, 30, 32,33  
Supercritical  $\text{CO}_2$ , 254  
Supplier, 114  
Suspension, 286  
Suzuki coupling, 74  
Suzuki-Miyaura coupling, 28, 29, 30  
Swern Oxidation, 41, 49

- Tablets, 285
- TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy radical), 47
- TEMPO/*N*-chlorosuccinimide oxidation, 47
- The Rule of Five, 216
- Thermal rearrangement, 24
- Thermolysis, 12, 13, 23
- Thieno[3,2-*b*]pyridin-7-one, 23
- Thieno[3,2-*b*]pyridine, 2-iodo-7-chloro, 24
- Thiophene, 3-amino, 23
- Thiophene, 3-amino, 2-carboxylic acid, methyl ester, 23
- Thiourea, 17
- Timelines, 115, 120
- Topicals, 288
- Toxicology, 21
- Trade Secret, 301
- Transcription, of the *ras*-protein, 73
- Transesterification, alkoxide-catalyzed, 76
- Transition-state, 45–46
- Tritiation, 196
- Triyl lithium, 8
- Tumor, growth and metastasis, 21
- Tumor-selective cytotoxicity, 37
- Unit Operation, 195
- Vapor diffusion, 228
- Vascular endothelial growth factor receptor-2 (VEGFR-2), 21
- VEGFR kinase inhibitor, 21
- Water Activity, 234
- Wet milling, 254
- Wittig reagent, 41, 43
- Workup, 177

